In an orthotopic pancreatic tumor model, targeting tumor-initiating cells (TICs) with MSC membrane-derived nanovesicles, known as “nano-ghosts,” loaded with a CXCR3 antagonist improved treatment efficacy and delayed tumor recurrence when combined with gemcitabine. Here, CXCR3 is linked to neoplasm.